Nanovaccines: An effective therapeutic approach for cancer therapy
Sangiliyandi Gurunathan,Pratheep Thangaraj,Lin Wang,Qilong Cao,Jin-Hoi Kim
DOI: https://doi.org/10.1016/j.biopha.2023.115992
IF: 7.419
2023-12-10
Biomedicine & Pharmacotherapy
Abstract:Cancer vaccines hold considerable promise for the immunotherapy of solid tumors. Nanomedicine offers several strategies for enhancing vaccine effectiveness. In particular, molecular or (sub) cellular vaccines can be delivered to the target lymphoid tissues and cells by nanocarriers and nanoplatforms to increase the potency and durability of antitumor immunity and minimize negative side effects. Nanovaccines use nanoparticles (NPs) as carriers and/or adjuvants, offering the advantages of optimal nanoscale size, high stability, ample antigen loading, high immunogenicity, tunable antigen presentation, increased retention in lymph nodes, and immunity promotion. To induce antitumor immunity, cancer vaccines rely on tumor antigens, which are administered in the form of entire cells, peptides, nucleic acids, extracellular vesicles (EVs), or cell membrane–encapsulated NPs. Ideal cancer vaccines stimulate both humoral and cellular immunity while overcoming tumor-induced immune suppression. Herein, we review the key properties of nanovaccines for cancer immunotherapy and highlight the recent advances in their development based on the structure and composition of various (including synthetic and semi (biogenic) nanocarriers. Moreover, we discuss tumor cell–derived vaccines (including those based on whole-tumor-cell components, EVs, cell membrane–encapsulated NPs, and hybrid membrane–coated NPs), nanovaccine action mechanisms, and the challenges of immunocancer therapy and their translation to clinical applications.
pharmacology & pharmacy,medicine, research & experimental